Fair value · Biodexa Pharmaceuticals Plc (BDRX) · updated 2026-10-22 · from 20-F FY2025
Biodexa Pharmaceuticals (BDRX): not enough filed data to read assumptions out of the price yet.
These methods need positive earnings and cash flow from the company’s SEC filings. The detailed valuation tools below still work with whatever has been filed.
At least two methods need a usable value to draw a range with these inputs.
Range with preset inputs
No preset range for this company yet.
The two ranges are identical because every input sits on a preset.
We don’t tell you what BDRX is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has BDRX’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.
Discounted cash flow
N/A
No revenue in the latest annual filing
Preset inputs — revenue-driven DCF from the latest filing
• No revenue in the latest annual filing
Implied by today’s price
Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price.
Not solvable from the price — Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price. Showing preset inputs.
This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what BDRX has actually filed, and the AI chat will reason it through with you.
Your inputs
Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.
Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.
-20.0%60.0%
How long stage-1 growth lasts.
1 yrs10 yrs
Slower growth after stage 1, before the terminal phase.
-20.0%30.0%
0 yrs10 yrs
Growth forever after the two stages. Above ~3% is rarely justified.
0.0%5.0%
The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.
